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Abstract
Mycobacterial infections and tuberculosis pose global public health threats. High tuber-
culosis morbidities and mortalities are due to the diagnosis problems among other 
causes. This chapter describes and compares diverse mycobacterial infections and tuber-
culosis diagnostic efforts and point-out the direction so as to inform areas of and motivate 
research toward early, rapid, and accurate diagnosis for effective TB control. We have 
grouped diagnostic approaches according to the type of sample taken for or organ tar-
geted during diagnosis. The sputum-based methods include smear microscopy, culture, 
and rat sniffing. Interferon-γ (INF-γ) release assays, transcriptional blood signatures, and 
proteomic profiling use blood samples while colorimetric sensor array (CSA) and mass 
spectrometry use urine samples. Patho-physiological methods include tuberculin skin 
tests (TSTs) and radiography. Chromatography and acoustic wave detection can also be 
used to diagnose TB from breath. Comparative description of these methods is based on a 
time frame to diagnosis, accuracy, cost, and convenience. The trend shows that there is a 
move from time-consuming, slow and narrow-spectrum to quick and broad-spectrum TB 
diagnostic procedures. The sputum-based and patho-physiological approaches remain 
conformist while blood-based procedures lead research developments. Absence of single 
best approach calls for synergistic research combinations that form accurate, rapid, 
cheap, and convenient package at point-of-care centers.
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1. Introduction
Tuberculosis caused by M. tuberculosis is the leading cause of human deaths from single infec-
tious agent and fall in the top 10 causes of deaths worldwide. More than 10 million people suf-
fered from TB in 2016 and the global case fatality and incident rates were 16% and 140/100,000 [1].
Inhalation of M. tuberculosis stimulates host cellular immune response with a consequence of 
either clearance of the organism or infection. Infection may result into latent mycobacteria infec-
tion (LTBI) (no clinical evidence) [2] or active tuberculosis (pulmonary or extra-pulmonary) [1].
The global LTBI prevalence is 23%, which is approximately 1.7 billion of the population [3]. 
About 5–15% of LTBI may progress to active TB [4]. LTBI is currently diagnosed by tuberculin 
skin test (TST) or gamma-interferon release assays (IGRA) [5]. On average the prevalence of 
active TB globally is 0.14% and the figures may vary according to regions [1].
The zoonotic potential of M. bovis constitutes a public health concern. Ingestion of M. bovis 
contaminated material is reported to be a primary cause of infection in humans and the result-
ing TB may take both pulmonary and extra-pulmonary form [6]. The burden of tuberculosis 
in humans due to M. bovis is variable in different countries, ranging from 5 to 28% with mor-
talities of 8.7% [6]. Therefore, this pathogen should be given due weight in TB diagnosis and 
consequently control plan.
According to WHO report, 53 million deaths have been averted from 2000 to 2016 following 
diagnosis and treatment. There is a big gap between diagnosis and treatment otherwise the 
number of deaths prevented could be even higher [1]. Every year the health systems fail to 
capture 3 million TB patients [7] some of them may be due to the nature of mycobacteria and 
diagnostic setup [6].
When prevention of pathogen-host contact is inadequate, early, rapid, and discriminative 
diagnosis become the primary factor for treatment success and reduction of further transmis-
sions. Inappropriate diagnosis of symptomatic patients with active TB, LTBI, or other con-
founding diseases, for example, sarcoidosis, usually lead to delayed or wrong administration 
of full TB treatment or prophylactic dose [8]. This chapter, therefore, focuses on mycobacterial 
infections and tuberculosis diagnosis by assessing and comparing different procedures so as 
to suggest a best diagnostic method(s) and research direction.
The assessment and comparison of diagnostic procedures in this chapter are based on either 
single or combination of features such as the type of sample tested, pathological, or mor-
phological changes or immunological reactions. Some of the known mycobacterial infections 
and tuberculosis diagnostic sample sources include sputum for smear, sniffing, and culture, 
blood for biomarkers such as interferon, inflammatory cells, proteins and transcriptomes, 
urine, and breath for volatile organic compounds (VOCs). Moreover, anatomical and physi-
ological changes in tissues can allow diagnosis of tuberculosis through imaging techniques 
and skin reaction. Among these procedures, IGRA, TST and transcriptomic studies can detect 
mycobacterial infections while smear microscopy, culture and sniffing results of sputum, 
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radiography, and volatile organic compound determination can detect active tuberculosis. 
The latter group of procedures is assisted by the appearance of clinical symptoms. As the 
form of mycobacterial detection differs among these methods, sensitivity, and time frame to 
diagnosis vary as well. Nevertheless, the goal remains to end TB by 2035 [7].
2. Blood tests in TB diagnosis
Whole blood sample can be used to diagnose both mycobacterial infections and tuberculosis based 
on the host immune response. Characteristics of blood parameters such as interferon-induced 
genes, myeloid genes, inflammatory genes and B and T-cells regulation genes, and proteomic 
profiles are used as markers in the detection of mycobacterial infections and tuberculosis [9].
2.1. Interferon-γ release assays (IGRAs)
IGRAs are immune cell-mediated in vitro blood tests that measure mononuclear cell (lym-
phocytes: T and B cells) release of interferon-γ (INF-γ) after stimulation by antigens specific 
for Mycobacterium. Following infection, the body immune response is triggered and immune 
cells such as macrophages, T-cells, B-cells, and natural killer cell are involved. Macrophages, 
which form the first defense line, engulf, kill, and eliminate Mycobacteria tuberculosis. Some 
M. tuberculosis escapes the immune mechanism and survives and replicate in macrophages. 
T-cells, especially CD4 and CD8 T-cells, produce cytokine—interferon-gamma, which in turn 
activate infected macrophages to produce reactive nitric oxide and related reactive nitrogen 
intermediates to kill the M. tuberculosis and eliminate it through the actions of phagosomes 
and lysosomes [10]. The lymphocytes can produce interferon-gamma in vitro whenever stim-
ulated by M. tuberculosis antigen. This feature is used to assist in the diagnosis of Mycobacteria 
tuberculosis infection. Principally, the lymphocytes of a person infected with M. tuberculosis 
release interferon-gamma when mixed with M. tuberculosis derived antigens. There are two 
enzyme-linked assays; enzyme-linked immunosorbent assay (ELISA), and enzyme-linked 
immunosorbent spot (ELISPOT) assay. The assays detect INF-γ release by lymphocytes of 
sample donor following exposure to antigens found on the M. tuberculosis complex (MTBC).
In ELISA based IGRA, fresh whole test blood sample is mixed with M. tuberculosis antigens 
and control. The antigen is made up of 6kDaA early secreted antigen target (ESAT-6), 10-kDa 
culture filtrate protein (CFP-10), and TB7.7 [11]. Normal saline is used as a control. The assay 
gives the concentration of INF-γ in international units per milliliter (IU/ml). The test result is 
considered positive when the difference in INF-γ response to the TB antigen between the test 
antigen value and the control value is greater than the cut-off of 0.35 IU [12].
Principally, the ELISPOT assay works on peripheral blood mononuclear cells (PBMCs) 
from a whole blood sample. The PBMCs are mixed with synthetic peptide antigens (ESAT-6 
and CFP-10) and the control and incubated to stimulate interferon-γ secretion by the cells. 
Secreted interferon-γ is captured by specific antibodies and accumulated as spots. Thus, 
ELISPOT assay gives the number of interferon-γ producing cells (spots). The test result is 
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considered positive when the difference in a number of spots between the test sample and 
the negative control is greater than eight (8) [13].
Both IGRAs have the ability to diagnose latent mycobacterial infection in 24 h following the 
one-time patient visit and submission of the blood sample to a health center [11]. The sensitiv-
ity of the IGRAs in adults is 80–90% when mycobacterium standard culture is used as gold 
[13]. In contrast to tuberculin skin test, IGRAs do not cross-react with Bacille Calmette-Guérin 
(BCG) antigen hence prior BCG vaccination does not cause false positives [11]. IGRAs cannot 
discriminate active tuberculosis from LTBI and its sensitivity is low in immunocompromised 
patients and children under the age of 5 years [13]. The cost of mycobacterium infection 
diagnosis by interferon- γ release assays is more than 40 USD per sample, which is higher 
compared to 10.56–25.97 USD for tuberculin skin test [14, 15]. This factor may influence the 
availability of and accessibility to this diagnostic service, especially in low-income countries.
2.2. Mycobacterium global gene signature/transcriptional blood signatures
Whole blood transcriptional signature can assist in distinguishing latent from active tuber-
culosis by showing features, which are not present in asymptomatic patients. Moreover, the 
transition from latent infection to active TB can be predicted by assessing the blood parameter 
[9]. This approach is important because of the reported 10–20% of detectable tuberculosis in 
asymptomatic individuals diagnosed with latent M. tuberculosis infection [16].
TB risk signature or global gene expression based on whole blood RNA genotyping poly-
merase chain reaction (PCR and sequencing) can be used to predict the chance of progres-
sion from latent to active TB. It has been reported that the expression of signature genes 
(that is quantities of functional RNA) increases toward active TB development in contrast to 
non-TB progressor (latent mycobacterium infection). For instance, Zak and colleagues [17] 
have reported a 16-gene signature with a sensitivity of 71.2% and specificity of 80% (95% 
CI: 66·6–75·2) at a 6 month time before tuberculosis diagnosis. This approach shows promis-
ing future of TB diagnosis as early as possible when samples are submitted since PCR and 
sequencing can give diagnostic results within 24 h.
Transcriptional blood signatures studies have been conducted in many parts of the world 
including high-income countries (US, UK, and German), middle-income countries (Brazil, 
South Africa, and Indonesia) and low-income countries (Kenya, Gambia, and Malawi) [9]. 
However, the procedure is under research and there is hope that it will become a handy tool 
in TB diagnosis and treatment decision.
2.3. Blood proteomic profiling/fingerprinting
Proteome, the entire set of proteins produced or modified by a cell, system or organism, vary 
with time, requirement, stress or disease state that cell, and system or organism experiences. 
Studies on types and levels of plasma or serum proteins show variations between individuals 
with LTBI, active TB and those under different stages of treatment. These features can be 
used to differentiate LTBI from active TB and other perplexing diseases. Plasma or serum 
protein peaks are identified using high-performance liquid chromatography (HPLC)-tandem 
matrix-assisted laser desorption/ionization-TOF-MS (MALDI-TOF-MS) and the results are 
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statistically analyzed to define mass spectral patterns. Results show unique abundant spectra 
(up-regulation) in plasma from subjects with active TB, which are distinct from those of sub-
jects with LTBI or controls.
Proteomic fingerprinting of plasma by surface-enhanced laser desorption/ionization—time 
of flight (SELDI-TOF) demonstrates that active TB can be discriminated from LTBI and other 
confounding diseases. Sandhu and colleagues [8] have reported that plasma from active TB 
patients had more distinct spectral peaks (at 5.8–11.5 kDa) than symptomatic LTBI and non-
LTBI controls. The procedure discriminates the active TB patients from the undifferentiated 
controls with an accuracy of 87% (sensitivity 84% specificity 90%). Moreover, active TB can 
be differentiated from symptomatic controls with LTBI at 87% accuracy (sensitivity 89%, 
specificity 82%) and from symptomatic controls without LTBI at 90% accuracy (sensitivity 
90%, specificity 92%). In this study Serum Amyloid A and transthyretin were reported as 
potential protein biomarkers for TB diagnosis. Similar procedure was also used by Agranoff 
and colleagues [18] on a serum to distinguish active TB patients from symptomatic controls, 
with an accuracy of 94% (sensitivity 93·5%, specificity 94·9%). Again, Serum Amyloid A and 
transthyretin were identified as potential biomarkers for TB diagnosis.
Liu and colleagues have also used SELDI-TOF MS to screen serum samples from TB patients 
and controls (lung cancer, pneumonia, chronic obstructive pulmonary disease, and healthy 
volunteers). Among different TB related peaks that were detected, fibrinogen with mass to 
charge ratio of 2554.6 Da was up-regulated in TB patients compared to controls. This dis-
crimination of TB patients from controls had an accuracy of 83.8% (sensitivity of 83.3% and 
specificity of 84.2%) and suggests that fibrinogen could be a potential TB biomarker [19]. A 
similar procedure was performed by Zhang and colleagues [20], whereby TB patients were 
differentiated from controls (non-TB controls such as pulmonary cancer, pneumonia, chronic 
bronchitis, emphysema, asthma and flu, and healthy subjects) with a sensitivity of 96.9% and 
specificity of 97.8% (accuracy up to 97.3%). The most distinct protein peak at mass/charge 
ratio of 5643 Da was up-regulated in TB patients and identified as orosomucoid protein.
In most proteomic finger printings for TB diagnosis, comparison of active TB patients, LTBI, 
and controls (healthy subjects or patients with other non-TB diseases) has been done. The 
peaks of identified protein biomarkers in controls have served as references. However, the 
identified protein biomarkers are not TB specific.
According to expert opinions, blood-based mycobacterial diagnostic procedures for example, 
IGRAs can give supporting information in diagnosis in some situations like extra-pulmonary 
TB, testing of negative acid-fast bacilli (AFB) in sputum and/or culture negative for M. tubercu-
losis, TB diagnosis in children, or in the differential diagnosis of infection with non-tuberculous 
mycobacteria (NTM) [21]. IGRA can also support the diagnosis of M. bovis infection when 
single intradermal comparative tuberculin test (SICTT) is negative [22].
3. Sputum tests in TB diagnosis
Sputum of patients with pulmonary TB contains mycobacterium pathogens, which serves 
a role in transmission. The presence of the pathogens and their features such as viability, 
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staining, or release of odor compounds are useful in diagnosis. Staining and culture are two 
common procedures, which use sputum sample to diagnose tuberculosis, especially active 
form. An emerging third method, which also utilizes sputum, is sniffing by trained African 
giant pouched rats, the Cricetomys gambianus.
3.1. Sputum sample collection
In TB diagnosis, a collection of right samples is necessary. First morning samples are pre-
ferred as the overnight accumulation of secretions give better results. Sputum samples are 
normally collected from self-reporting presumptive TB cases at TB clinic. For samples col-
lected far away from the diagnostic center, the samples are collected in transport medium, 
cetyl-pyridinium chloride (CPC) [23] for best subsequent results.
3.2. Ziehl Neelsen and fluorescent staining
A smear is made by even spreading of sputum over the glass slide to make a 20 mm by 10 mm 
eclipse shape. It may be dried and fixed by heat.
Smears from sputum samples are commonly stained using Ziehl Neelsen (ZN) or by fluores-
cence staining technique and examined microscopically for the presence of AFB. AFB testing is 
done as a screening procedure at the point of sample collection and on arrival at TB reference 
laboratory before culture and molecular confirmation. The waxy mycobacterial cell wall of myco-
bacterium is resistant to stain by conventional dyes and in one way the phenol-carbolfuchsin 
stain is forced to penetrate the cell wall by gentle heating underneath the slide flooded with 
carbolfuchsin. Then acid decolorizing solution is applied to remove the dye in cells, tissue, and 
any organisms in the smear except mycobacteria, which retain the dye. After decolorization, the 
smear is counterstained with either malachite green or methylene blue, which stains the back-
ground material green or blue, respectively. The contrasting background color enables the red 
Acid-Fast Bacilli to be visualized under a light microscope using the 100x oil immersion objective.
On the other hand, sputum smear can be stained with Auramine O or Auramine rhodamine 
dye and decolorized by a decolorizing agent (containing ethanol and hydrochloric acid). 
Counterstaining of the background by potassium permanganate enables visualization of 
orange-yellow acid-fast mycobacteria against a black back ground under a fluorescence 
microscope.
On comparison, fluorescent microscopy is faster in giving results (1 min) compared to ZN 
stain (4 min) and more sensitive (up to 97%) than ZN staining (up to 94%) and generally the 
accuracy of fluorescent microscopy is higher (Area Under the curve (AUC) = 96) compared to 
ZN staining (AUC = 94). However, due to resources constraint, ZN staining is more popular 
in low-income TB endemic areas [24].
3.3. Mycobacterial culture and molecular characterization
Culture isolation of mycobacteria is the gold standard method for TB diagnosis. Sputum 
smear stain positive samples are a good candidate for culture and molecular characterization. 
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However, manipulation of suspected mycobacterial samples should be handled in a contain-
ment facility to minimize the danger of exposure to personnel and the surrounding environ-
ment. If samples are collected far from the culture laboratory, and to prevent contamination, 
transport in CPC is recommended. Culturing of such samples should be within 7–8 days of 
collection and storage has given accurate results compared to culture from non-CPC stored 
samples [25]. Recent reports have shown good yield from CPC stored sputum samples for up 
to 21 days [26]. This is relevant in low-income countries where focal sample processing and 
culture centers are far from collection sites. Transport and storage times are worth noting as 
positivity from culture has been reported to be significantly affected beyond 2 weeks [27].
3.3.1. Sputum sample processing, culture, and identification
During sample processing, the sputum-CPC mixture is normally concentrated by centrifuging 
at 4000 rpm for 15 min, supernatants poured off into a splash proof container. The sediments 
can then be mixed with 20 ml of sterile distilled water, suspended by inverting the tubes 
several times, and then centrifuged at 3500 rpm for 15 min. The supernatant is then removed 
with the remaining pellets re-suspended in water for the inoculums ready for culture. Two 
Löwenstein-Jensen slants, one containing 0.75% glycerol and the other 0.6% pyruvate are used 
for inoculation of the sediments and incubated at 37°C. Growth of Mycobacterial inoculum is 
examined weekly for 8 weeks; at this juncture cultures with no growth after 8 weeks should 
be considered negative.
3.3.2. DNA extraction procedures
Several methods are available for extraction of mycobacterial DNA and follow pre-existing 
protocols depending on the purpose. However, boiling a loop full of bacteria in 100 μL H2O at 80°C for 60 min can suffice to provide sufficient DNA for subsequent analysis. The crude 
DNA extracted as per protocol is ready for subsequent analyses or storage at −20°C until 
typing is done. The most used genotyping methods for mycobacterium DNA are both poly-
merase chain reaction (PCR)-based spoligotyping; and mycobacterial interspaced repetitive 
units-variable number tandem repeat (MIRU-VNTR) typing. These techniques are useful and 
can characterize mycobacterial DNA to strain level and later differentiate into sub-lineages 
that despite enabling the establishment of transmission chains [28] can assist the mapping of 
TB strains across regions. This can be done by matching strains in question to existing myco-
bacterium database at Mtb complex (http://www.MIRU-VNTRPlus.org/). Whole genome 
sequencing can be done to further characterize mycobacteria pathogens. Clinically, whole 
genome sequencing for M. tuberculosis has an advantage in the sense that it provides a more 
rapid and comprehensive view of the genotype of the pathogen, and with the timely and 
reliable prediction of drug susceptibility including detection of resistance mutations in clini-
cal samples [29]. Despite the robust software and database tools, Whole genome sequencing 
needs to be developed for its full potential; it provides the highest resolution when investigat-
ing transmission events in possible outbreak scenarios [30]. All these methods are geared 
at improving treatment outcomes when integrated into routine diagnostic workflows, early 
reporting of drug resistance rather than dependence on phenotypic drug-susceptibility tests 
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[31]. In our context, we will discuss other characterization techniques, particularly spoligo-
typing, and MIRU-VNTR genotyping methods as our main focus rather than mycobacterium 
whole genome sequencing.
3.3.3. Spacer oligonucleotide typing (Spoligotyping)
In humans, TB infection is mostly due to MTBC, which comprises of a group of seven geneti-
cally similar species [32] namely M. tuberculosis, M. bovis, M. africanum, M. microti, M. canettii, 
M. pinnipedii, and M. caprae. To differentiate such genetically closely related species, special 
molecular techniques have been in place for quite some time now. Fortunately, despite the high 
genetic homogeneity among the members, they display divergent phenotypes, eliciting different 
pathologies, and while some show a degree of host specificities [33]. These qualities have made 
it possible to differentiate mycobacteria species to strain level and epidemiologically, determin-
ing their transmission chain using molecular techniques. Spoligotyping is among PCR-based 
technique that is used in combination with other molecular methods to establish strain variabil-
ity in a given population. Using commercially available kits, spoligotyping can be done with 
reference to existing protocols described previously by Kamerbeek et al. [34]. This PCR-based 
fingerprinting method detects the presence or absence of 43 variable spacer sequences situated 
between short direct repeat (DR) sequences in the M. tuberculosis genome. The DNA from refer-
ence M. tuberculosis H37Rv and M. bovis BCG clones are commonly used as positive controls 
while autoclaved ultrapure water is used as a negative control. Visualization of presence (black 
squares) or absence (blank squares) of variable spacer sequences on film is achieved after incu-
bation with streptavidin-peroxidase and detection of hybridized DNA using chemiluminescent 
detection liquid followed by exposure to radiography uses electromagnetic radiations (x-ray) 
film. Resulting spoligotypes are normally reported in octal and binary formats and compared 
to existing patterns in an international spoligotyping database profiles (SpolDB4.0) [35] avail-
able at http://www.pasteur-guadeloupe.fr:8081/SITVITDemo/). Spoligotype patterns can then be 
grouped as spoligotype international types (SITs) if they share identical spoligotype patterns with 
patterns present in the existing database. Such strain comparisons using SITs are used to identify 
TB strains circulating in the population as well as new strains and assign names for new strains, 
which cannot be found in previous studies where possible [35, 36]. By using spoligotyping, it is 
possible to map TB strains with their diversity within and between regions [37], not only revealing 
differences in circulating M. tuberculosis strains [38] but also identification of new strains [39] even 
within the country in endemic areas. Further, molecular characterization has yielded molecular 
type patterns suggestive of similar strains in humans and in wild ungulates [40].
3.3.4. Mycobacterial interspaced repetitive units-variable number tandem repeat (MIRU-
VNTR) typing
This is a PCR-based method that exploits the presence of interspaced repetitive DNA in 
mycobacterium and other genomes to characterize mycobacteria strains and within strains 
circulating in a given population. In combination with spoligotyping, the method forms 
a large-scale, high-throughput genotyping of M. tuberculosis [28]. The method is based on 
the presence of more extensive loci that contain variable number tandem repeat (VNTR) 
of genetic elements named mycobacterial interspersed repetitive units (MIRUs) located 
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mainly in intergenic regions dispersed throughout the M. tuberculosis genome [28, 41]. The 
method combines the analysis of multiplex PCRs for the target loci on a fluorescence-based 
DNA analyzer with computerized automation of the genotyping [42]. Initially, the geno-
typing system used only 12 loci for epidemiological molecular studies in combination with 
spoligotyping, but now a more discriminatory 24 loci MIRU-VNTR is in place. This current 
genotyping system in combination with spoligotyping has been found to be 40% superior in 
a number of types among isolates from cosmopolitan origins, compared to those obtained 
with the original set of 12 loci [28]. Nevertheless, researchers still continue to optimize the 
24-loci MIRU-VNTR genotyping in an attempt to reduce the turnaround time of typing and 
financial burden [33] although the MIRU-VNTR typing manual [43] remains primary and 
key guide to all MIRU-VNTR typing of MTBC strains.
The standardized 24 loci MIRU-VNTR typing protocol by Supply et al. [42] is performed using 
primers that amplify 24 polymorphic loci on the mycobacterial genome per DNA isolate. The 
number of tandem repeat units present at each locus is then calculated from the size of DNA 
fragments according to a standardized table (http://www.MIRU-VNTRplus.org). The results 
can be expressed in digital format where each number represents the number of repeat copies 
at a particular locus. Phylogenetic analysis and creation of dendrograms can then be done 
using MIRU-VNTRplus (http://www.MIRU-VNTRPlus.org/) to generate a categorical-based 
NJ-Tree dendrogram to enable comparison of strain genotypes [44]. Creation of dendrogram 
from phylogenetic analysis enables the establishment of transmission links.
3.4. Sputum sniffing by African giant pouched rats
In recent years diagnosis of pulmonary TB in humans has taken a turn to involve Trained 
African giant pouched rats (Cricetomys gambianus). The procedure takes advantage of the abil-
ity of the African giant pouched rats to detect and discriminate odor of volatile compounds 
produced by mycobacteria [45]. Weetjens and his colleges extended the dimension of research 
from landmine detection to TB diagnosis [46].
The rats are trained to sniff heat-inactivated sputum from presumptive TB patients for the 
purpose of discriminating positive samples from negatives. According to Weetjens and col-
leagues [46], the rats are domesticated, bred and that training is done to the young rats. At the 
age of 4 weeks, young rats are identified and assigned to a specific trainer. This is accompa-
nied by socialization and habituation learning. Then the rats are trained to locate the sniffing 
hole in the cage and sniffing at the age of 8 weeks. Discrimination of odor is introduced and 
multiple sample evaluation follows, at the age of 8 months the rats start operational training. 
During training, the rats learn to associate odor of TB volatiles with reward (food: peanut or 
banana). The trained rats sniff holes with sputum samples in the cage. The negative samples 
are sniffed for less than a second and ignored while for the positive samples, the rat will fix 
their nose at the hole for at least 5 seconds. In this exercise, each of positive sample detection 
is accompanied by a reward in form of food [46].
The rats can detect M. tuberculosis-specific volatiles such as nicotinate, methyl para-anisate, 
and ortho-phenylanisole from sputum infected with MTBC, M. avium, M. intracellulare and 
other NTM [47]. The detection has been reported to be at 80.4% sensitivity, 72.4% specificity, 
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and 73.9% accuracy [47]. Sample evaluation results are potentiated by use of multiple rats 
(e.g. group of four) and positive indication by at least one rat criteria has been reported to be 
more sensitive than multiple positive indications [48].
Cricetomys gambianus are resistant to TB infection [48]. The rats can detect mycobacteria in 
sputum in as low concentration as a few bacteria in less than 10 sec [49]. In contrast to a 
trained microscopist who can examine less than 50 samples a day, the rats can detect hun-
dreds of samples per day before exhaustion [50]. These features make sputum sniffing by the 
giant African rats a potential rapid screening test. Such technique has been used in Tanzania 
and Mozambique as a second line screening after ZN staining sputum smear microscopy 
where 44% increase in TB case detection rate has been reported [48]. However, sputum sniff-
ing by the African giant rats does not guarantee 100% accurate TB diagnosis. Although this 
disqualifies it as a stand-alone TB diagnostic or first line screening test for presumptive test 
it can be useful in increasing TB cases among smear-negatives especially in low-income TB 
endemic countries where diagnostics capabilities are limited [51].
Moreover, TB diagnosis by sniffing rats works in active TB, it may not be handy in latent TB 
cases. Furthermore, the rats are living creature whose health status needs attention and any 
anatomical, physiological, or functional deformity may impair TB diagnosis.
4. Patho-physiological assessment in TB diagnosis
Pathological and or physiological changes in the body can be used to diagnose mycobacteria 
infections or TB. Two common in vivo methods, TST, and chest radiography are presented in 
this chapter.
4.1. Tuberculin skin test (TST)
The TST is the internationally recognized standard method to identify infection with M. tuber-
culosis and M. bovis. Intradermal tuberculin tests based on eliciting a delayed-type hypersensi-
tivity response, which is mediated by a population of sensitized T-cells and takes some weeks 
to develop after infection [52]. The TST use the purified protein derivative (PPD) tuberculins 
that have been derived from M. bovis and M. tuberculosis for detection of latent TB in cattle and 
in human, respectively.
Techniques that are used for tuberculin skin testing in human include; Multiple puncture tests 
(tine test, heaf test, and MONO-VACC test) and intracutaneous injections either given by the 
jet injector or by the Mantoux test [53]. Multiple puncture tests introduce tuberculin into the 
skin through tuberculin-coated prongs while the Mantoux skin test involves the intracutane-
ous injection of tuberculin into the volar surface of the forearm [54]. The Mantoux test is 
recommended for clinical assessment or screening since it is more sensitive and specific than 
the other methods. The reported sensitivity and specificity of TST in human ranges from 59 to 
100% and 70 to 100%, respectively [53].
There are several factors that are associated with false negative results of intradermal skin test 
in humans. These include recent or advanced TB, severe malnutrition, immuno deficiency 
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due to the HIV or immunosuppressive chemotherapy, co-infections with viral, bacterial and 
fungal diseases affecting lymphoid organs (lymphoma, chronic lymphoid leukemia sarcoid-
osis), metabolic derangement (chronic renal failure), stress (surgery, burns, and mental ill-
ness), and live vaccination (measles, mumps, and polio) [53, 54]. False positive reactions are 
more commonly attributed to co-infection or pre-exposure to other related NTM in cattle and 
human [55] and BCG vaccination in human [56].
Despite of the several major limitations, TST has been, until recently, a useful procedure for 
detecting LTBI [57] and most widely used test for control of Bovine TB due to the low-cost, 
low logistical demands, well-documented use, and its ability to screen the entire cattle popu-
lations [52]. Due to the limitations of the sensitivity and specificity of the skin tests, newer 
ancillary in vitro diagnostic assays for latent tuberculosis has been developed, which mea-
sures the production of interferons in whole blood upon stimulation with PPD [52].
4.2. Imaging in TB diagnosis
Radiography uses electromagnetic radiations (x-rays) to visualize internal body organs. Chest 
radiography is used for imaging lungs, airways, ribs, heart, and diaphragm. The rays are 
allowed to pass through tissues and captured by a film. Variation of absorption of x-rays by 
different tissues enables contrasting visualization. Hard tissues, for example, bones absorb 
more rays and appear dense while soft tissues allow more passage of rays and appear light. 
Knowledge of anatomy is important for diagnostic interpretation.
According to WHO [58] chest radiography is indicated as a pulmonary TB diagnostic tool 
for triaging, screening and as a diagnostic aid when clinical pulmonary TB cannot be con-
firmed bacteriologically. Chest radiography can also be used in the evaluation of TB treatment 
response. It is, therefore, part of an algorithm within health care system. It can be used to dis-
tinguish between active and inactive pulmonary TB based on a temporal evaluation of radio-
graphs whereby the latter is characterized by stable radiographic pictures for 6 months [59].
Most common chest radiographic findings of TB include lymphadenopathy, parenchymal 
opacities, obstructive atelectasis, pleural effusion, cavitations, and tuberculomas [59]. Chest 
radiography has high-sensitivity (97%, 95% CI 0.90–1.00) and low-specificity (67%, 95% CI 
0.64–0.70) [60]. It can detect any abnormality in the chest including those related to other 
non-TB pathological conditions. Other imaging techniques such as computed tomography 
(CT) and Magnetic resonance imaging (MRI) are superior to chest radiography and can be 
used for reference. It is important to note that besides the low specificity, chest radiography is 
expensive in terms of equipment and skilled labor, especially in low-income endemic areas.
5. Urine sample tests in TB diagnosis
Advocacy toward non-invasive, non-sputum simple TB diagnosis has pushed research into 
different directions including the use of urine sample from presumptive TB patients. There 
are a number of target TB biomarkers in urine including volatile compounds, proteins, and 
TB antigen.
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In a study by Cannas and colleagues [61], traces of mycobacteria DNA were detected in the 
urine of TB patients at 79% while the controls were negative. In addition, proteins produced 
in lung lesions and excreted in urine were also recognized by immunoglobulin G (IgG) from 
active TB patients [62]. Other TB protein biomarkers in the urine of TB patients have been 
reported by Young and colleagues [63]. In a similar study, Lim and friends [64] tested urine 
for TB by using a colorimetric sensor array (CSA). Urine headspace analysis showed discrimi-
nation between TB and control patients with 85.5% sensitivity and 79.5% specificity. Analysis 
of volatile organic compounds using headspace gas chromatography/mass spectrometry 
(GC/MS) showed increased levels of o-xylene and isopropyl acetate and decreased levels of 
3-pentanol, dimethylstyrene, and cymol in the urine of TB patients compared to controls with 
respiratory diseases other than TB [65].
Urine-based TB diagnostic procedures can only detect biomarkers related to active TB 
and not latent TB. However, the promising feature is that it can detect extra pulmonary 
TB. Nevertheless, more researches are required to unravel the practicability of the tests.
6. Breath tests in TB diagnosis
Volatile organic compounds (VOCs) in breath have shown to contain biomarkers of active 
pulmonary tuberculosis derived from the infectious organism (metabolites of M. tuberculosis) 
and from the infected host (products of oxidative stress).
6.1. Breath sample collection
According to the method described by Braden and colleague, [66], a portable breath collection 
apparatus (BCA) is used to capture the VOCs in 1.0 L breath and 1.0 L room air on to separate 
sorbent traps. The geometry of the breath reservoir of the BCA is set to ensure that the sample 
comprises >99% alveolar breath. Subjects wear a nose-clip and respire normally for 2.0 min 
through a disposable valve mouthpiece with a bacterial filter to prevent mycobacterial con-
tamination of the instrument. The mouthpiece and filter present low-resistance to respiration 
ensuring that samples are collected without causing any discomfort to patients.
6.2. Breath sample analysis
The VOCs captured in the sorbent traps are then analyzed in the laboratory according to 
the method described by Phillips where an automated thermal desorption, gas chroma-
tography, and mass spectroscopy (ATD/GC/MS) is employed. To quantify peak areas and 
control for drift in instrument performance, an internal standard is normally run with every 
chromatographic assay of breath and air (0.25 mL 2 ppm 1-bromo-4-fluorobenzene, Supelco, 
Bellefonte, and PA).
Chromatographic data collected are then converted into a series of data points by segmenting 
them into a series of time slices. The alveolar gradient of each time slice is then determined 
(i.e. abundance in alveolar breath minus abundance in ambient room air) [67, 68].
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For each of the time slice, the alveolar gradient is calculated by taking: ¼ Vb /Ib Va/Ia.
Where, Vb is the integrated abundance of analytes detected by mass spectroscopy in a breath, 
and Ib is the area under the curve (AUC) of the chromatographic peak associated with the 
internal standard. Va and Ia denote corresponding values derived from the associated sample 
of room air.
6.3. Identification of biomarker time slices
The alveolar gradients are identified by comparing the patients positive or negative for active 
pulmonary TB and rank them as candidate biomarkers according to the value of the C-statistic 
that is, the AUC of the receiver operating characteristic (ROC) curve [69]. The Kovats Index 
windows for active TB are clearly distinct from controls in a test that takes 6 min. The detec-
tion of TB biomarkers is 80% accurate with 71.2% sensitivity and 72% specificity [70].
TB testing using breath provides hope for a future non-invasive diagnostic procedure. Phillips 
et al. have put effort to assess the presence of volatile organic compounds in the breath of 
active TB patients. A special device collected and concentrated breath from TB patients and 
controls at point-of-care centers. However, the procedure requires special set up and equip-
ment and may not be suitable in low-income endemic settings.
7. Challenges in diagnosis of tuberculosis
In the diagnosis of tuberculosis in both humans and animals, the challenges have always been 
the availability of better and affordable diagnostic methods. While conventional tests such as 
ZN test for sputum has been in place and are the gold standard, it can miss some cases due to 
low-sensitivity. Mycobacterial cultures can improve detection but takes longer to get results. 
Molecular characterization to nucleotide level that is, through sequencing is perfect but usu-
ally unaffordable in low-income countries diagnostic settings. In addition, DNA isolation, 
species identification, and obtaining cultures from a sophisticated system may face limitations 
as well. All these challenges necessitate for advocacy focusing on innovations that deliver bet-
ter tools to confidently diagnose TB and at affordable costs [71]. Although, international and 
national laboratory partnerships are encouraged particularly to boost diagnostic services in 
resource-poor countries, the need for diagnostic tests that allow rapid testing at point-of-care is 
necessary [72]. However, all these need acceptance by health authorities in respective countries 
for incorporation into countries diagnostic algorithms while ensuring inherent and adequate 
quality assurance programs in dedicated laboratories. In marginalized communities, refusal 
of diagnosis, high indirect costs, and anticipated treatment side-effects have posed barriers to 
TB diagnosis [73]. All these need to be considered if we want to perform right diagnosis and 
management of tuberculosis across endemic regions. Screening programs for both human and 
animal tuberculosis could cut the costs of modern molecular diagnostics and characterization 
but these programs are costly and might currently not be of primary priority by responsible 
authorities. Otherwise, screening programs despite potentially expected high initial capital 
investment, their value on cutting down diagnostic costs for TB cannot be overemphasized.
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8. Features of desired TB diagnostic procedure
Currently, the procedure includes medical history, physical examination, chest radiography, 
TST, serologic tests (e.g. IGRA), microbiologic smear (e.g. ZN), and culture [59].
The distinction between and transition from LTBI to active TB as well as differentiation of 
stages of active TB toward recovery are attributes of a nearly perfect TB diagnostic proce-
dure. This should be coupled with the ability to detect early stages of the TB related health 
status and a short time to diagnosis. Applicability and convenience of diagnostic (set of) 
procedures in all life settings are factors to consider when planning a TB diagnostic package. 
It is not easy to find the majority of these merits in one procedure but a combination of both 
conventional and molecular tools starting from screening to diagnosis can facilitate the mis-
sion of fighting TB.
9. Diagnostic research direction
TB diagnostic research course moves toward blood parameters such as immune response 
components, protein, and pathological parameters or other tissues (cerebral-spinal fluid). 
Such parameters shed more light for future informed diagnosis including status and stage 
of infection or treatment. Converging different research routes may provide an outcome, 
which shows effects of interactions. For sure there may be antagonistic but also synergistic 
outcome. For instance, an approach that will detect the presence of the pathogen and also 
inform about immune status, pathological, or prognostic prediction is required. All in all, 
instituting programs that focus on screening tests for early detection of the disease can per-
fectly fit in the strategy of disease control and management. In so doing, disease elimination 
can be made possible.
10. Conclusion
There is no single best diagnostic approach that can suit all settings including low-income 
endemic areas. Some procedures are weak in some aspects and can be complemented by 
others synergistically. This calls for research focus on combinations of procedures and pro-
grams, which give out quick and discriminatory results. For instance, a diagnostic procedure 
should be able to detect LTBI, active TB and different stages of recovery during treatment. 
Nevertheless, having programs that focus on screening of the disease in our population 
will definitely reduce diagnostic as well as treatment costs. This can be done particularly 
through active case finding (ACF) that will enable screening of TB by systematically search-
ing individuals who would otherwise spontaneously not nock the door and present for care 
at health facility. In so doing early case detection will be increased particularly in marginal-
ized populations [73–76]. Such areas are devoid of reliable and dedicated diagnostic facility 
under normal settings.
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